‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

  • Published on 9th January 2024 by GSK
Share

Researchers are testing innovative new ways to protect people against infectious disease – and pursuing effective vaccines to fight bacteria and viruses that have eluded them for decades.

The technology used to create vaccines in record time during the pandemic marked the start of a new age in the field of vaccine development. 

Scientists are turning to an array of novel approaches to prevent life-threatening diseases. Their ambitions include targeting more strains of pathogens – disease-causing organisms – and different diseases in single vaccines, stimulating stronger immune responses and providing longer-lasting protection.  

In some cases, researchers are moving closer to creating vaccines that have eluded them for decades. If they reach the finish line, these discoveries could help tackle infectious diseases that take a significant toll around the world despite huge progress. 

“The roar I hear is the next stage of the rocket firing,” says Dr William Schaffner, a professor of preventive medicine at Vanderbilt University and the medical director of the National Foundation for Infectious Diseases in the US.  

“We’re at the beginning of a period of very exciting technological and scientific innovation. That will lead us to the development of any number of new vaccines over what I hope is a relatively short period of time.” 

One such new technology showing promise is the Multiple Antigen Presenting System, or MAPS.  

MAPS aims to elicit a stronger immune response against multiple types of a particular bacterium. In the case of pneumococcal bacteria, approximately 100 distinct types have been identified throughout the world. Pneumococcal diseases, including pneumonia and meningitis, are estimated to kill 1 million children a year, according to the World Health Organization. Older adults are also at risk of serious illness and death from pneumonia.

The goal is to provide broader protection by combining multiple sugar and protein antigens – substances that are recognised by the immune system – from the surface of the bacteria in one vaccine, which will activate different parts of the immune system. The sugar antigens, called polysaccharides, have the potential to stimulate an antibody response, while the protein antigens can elicit an additional T-cell and antibody response. The unique way of linking the antigens together in a modular fashion, like connecting Lego blocks, is designed to overcome the complex chemistry of traditional vaccines. It could also make manufacturing new vaccines quicker and easier.

MAPS Vaccine Candidate animation

“It’s a genuinely better way of making anti-bacterial vaccines,” says Dr Phil Dormitzer, the global head of vaccines research and development at GSK, which is now developing MAPS technology.  

“Overall, there’s an attractive simplicity to the system.” 

The approach has wider potential and, as infections become increasingly hard or sometimes impossible to treat due to drug resistance, it could also become an important tool in countering bacterial pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae that often spread in healthcare facilities and are prone to develop resistance against current treatments.  

Health care providers will need vaccines, along with new drugs, to counter the rising threat of superbugs. An estimated 1.2 million people die each year as germs evolve and develop the ability to survive the drugs designed to kill them. By preventing those infections from occurring in the first place, vaccinations can curb the use of antibiotics – a key driver of antimicrobial resistance, or AMR.  

“That’s not being fully appreciated,” Dr Schaffner continues. “We haven’t documented that nearly as completely as we might have, in part because AMR wasn’t the problem that it is today.” 

A vaccine manufacturing production line in action
A vaccine manufacturing production line in action

The research that paved the way for MAPS started in the late 1990s. 

Dormitzer, then a fellow in the infectious disease program at Harvard Medical School, recalls crossing paths with another young doctor, Richard Malley, and hearing about his nascent research at Boston Children’s Hospital. Malley had just started investigating new vaccines against pneumococcal diseases and other pathogens. 

At the time, Malley says that scientists – including himself at one point – often regarded vaccine research as “pedestrian”. However, when he witnessed the impact of a new vaccine, which virtually wiped out a form of meningitis in young children in the US, it opened his eyes to lifesaving new possibilities. 

“I started thinking about how powerful a new vaccine introduction can be,” he says.  

After a chance meeting in 1997 with Porter Anderson, one of the inventors of the pneumococcal vaccine, Malley jumped at the chance to collaborate, a decision that eventually led to the formation of Affinivax, a biotech company that GSK acquired in August 2022. 

Today, vaccine technology development is anything but dull.  

The need for a COVID-19 vaccine accelerated work already progressing before the pandemic and underscored the importance of quick and efficient vaccine development. In just the first year of the pandemic, COVID shots may have averted about 20 million deaths, according to researchers at Imperial College London.  

“Vaccine scientists are now seeing a breadth of investigations that didn’t exist before,” says Malley, who has taken on the role of chief MAPS scientist at GSK along with his responsibilities at Boston Children’s Hospital. “I was going to say it’s a crossroads, but it’s not a crossroads. It’s like tributaries, and we must decide how many of them we can follow.” 

A broad portfolio of vaccine technologies, alongside MAPS, will be critical in the bid to prevent death and disease from viral and bacterial pathogens.  

GSK scientific image of the MAPS vaccine technology
A scientific image of the MAPS vaccine technology

After proving that messenger RNA, or mRNA, was a suitable vaccine technology to respond to COVID-19, researchers are studying what else it can achieve against targets such as influenza. While many traditional vaccines rely on weakened or inactivated parts of a virus to provoke an immune response, mRNA vaccines deliver detailed instructions to the body’s cells to make key protein antigens, effectively turning them into mini vaccine factories. 

In pursuing future flu or COVID vaccines, mRNA is an important tool, says Dormitzer, who helped develop one of the highly effective COVID shots before joining GSK about a year ago. 

Yet other approaches, such as protein subunit vaccines which use fragments of a pathogen to trigger immunity, remain key. Adjuvants, ingredients that enhance the magnitude and durability of the immune response to an antigen, will also play a principal role. 

Instead of chasing after viruses and trying to introduce new vaccines every time a new variant arises, another priority is creating vaccines that can provide broader protection, including against multiple strains.  

At the same time, scientists are studying whether they can deliver better protection from vaccines delivered via the nose rather than injected into the arm, while trying to prevent diseases from worsening in people who are already infected through so-called therapeutic vaccines or targeted immunotherapies.

Read more articles like this in GSK's Behind the Science Magazine here.

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.